A5052499885- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Shoulder Injury and Treatment
- T-cell and B-cell Immunology
- SARS-CoV-2 and COVID-19 Research
- Trauma Management and Diagnosis
- Shoulder and Clavicle Injuries
- Virus-based gene therapy research
- SARS-CoV-2 detection and testing
- Acute Lymphoblastic Leukemia research
- RNA Interference and Gene Delivery
- Knee injuries and reconstruction techniques
- Total Knee Arthroplasty Outcomes
Baptist Health South Florida
2023-2024
Johns Hopkins University
2021-2024
Sidney Kimmel Comprehensive Cancer Center
2021-2024
Baptist Hospital of Miami
2023
Johns Hopkins Medicine
2021
Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. Natural Killer (NK) cells can elicit an antileukemic response via a repertoire activating receptors that bind AML surface ligands. NK-cell adoptive transfer is safe but thus far has shown limited anti-AML efficacy. Here, we aimed overcome this limitation by engineering NK express chimeric antigen (CARs) boost their...
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 3</p>
Background: Degenerative tendon changes are common as people age, which can increase the likelihood of tendinous injuries. The outcomes repairing hamstring avulsions in patients >40 years after a rehabilitation protocol without postoperative bracing relatively unknown. Purpose: To assess functional and determine rerupture rate surgical repair complete proximal while following nonbracing protocol. Study Design: Case series; Level evidence, 4. Methods: A total 27 with acute, underwent...
CD19-specific chimeric antigen receptor (CAR) T-cell therapies, including the FDA–approved tisagenlecleucel, induce high rates of remission in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, post-treatment relapse remains an issue. Optimal management B-ALL after tisagenlecleucel treatment elusive, and continued tracking outcomes is necessary to establish a standard care for this population. We sought evaluate on real-world use contemporary...
H84T-Banana Lectin (BanLec) CAR-NK cells bind high mannose glycosites that decorate the SARS-CoV-2 envelope, thereby decreasing cellular infection in a model of SARS-CoV-2. H84T-BanLec are innate effector cells, activated by virus. This novel agent is promising therapeutic, capable clearing circulating virus and infected cells. Banana binds glycans on viral envelopes, exerting an anti-viral effect. A point mutation (H84T) divorces BanLec mitogenicity from antiviral activity. contains...
Abstract Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. NK cells can elicit an anti-leukemic response via a repertoire activating receptors that bind AML surface ligands. cell adoptive transfer is safe but thus far has shown limited anti-AML efficacy. Here, we aimed overcome this limitation by engineering express chimeric antigen (CARs) boost their activity,...
Background: Medial meniscal root repairs are devastating injuries that can cause long-term knee problems if not properly addressed. Some common issues when addressing these surgically include the “bungee-cord” effect seen with implants sit too far from tibial plateau surface and loss of tension on sutures after cycling repair. This video will discuss presentation a patient medial repair treated novel technique to counteract aforementioned issues. Indications: Based patient’s tear minimal...
Rotator cuff tears are rare injuries in professional athletes who participate contact sports, and limited data exist to guide players team physicians regarding outcomes after surgical management.
Chimeric antigen receptor (CAR) T cells can effectively treat leukemias, but sustained antitumor responses be hindered by a lack of CAR T-cell persistence. Cytotoxic effector are short-lived, and establishment CAR-T with memory to ensure immune surveillance is important. Memory depend on cytokine support, IL7 activation the (IL7R) being critical. However, IL7R surface expression negatively regulated exposure IL7. We aimed support persistence equipping IL7Rα signal. engineered constitutively...
<div>Abstract<p>Chimeric antigen receptor (CAR) T cells can effectively treat leukemias, but sustained antitumor responses be hindered by a lack of CAR T-cell persistence. Cytotoxic effector are short-lived, and establishment CAR-T with memory to ensure immune surveillance is important. Memory depend on cytokine support, IL7 activation the (IL7R) being critical. However, IL7R surface expression negatively regulated exposure IL7. We aimed support persistence equipping IL7Rα...
<p>Human primary T cells can be engineered for stable IL7 pathway activation. <b>A,</b> Schematic of CCR and sIL7, as well transgenes into cells. <b>B,</b> Transduction efficiency to express GFP only, IL7R + GFP, or secrete was measured by detecting eGFP positivity expression with flow cytometry. <b>C,</b> Concentration in the supernatant sIL7-transduced control (G-o) cytokine-free culture medium. <b>D,</b> Immunophenotype...
<p>T cells with IL7 pathway activation expand and circulate <i>in vivo</i>. <b>A,</b> Schematic of experimental design. NSG mice were injected on day 0 10<sup>7</sup> T expressing a ffLuc reporter. BLI was conducted biweekly, peripheral blood collected days 15 30. One group treated ffLuc-only–modified intraperitoneal injections daily from 1 to 21. <b>B,</b> monitoring T-cell expansion. <b>C,</b> Quantified radiance per mouse....
<p>Human primary T cells can be engineered for stable IL7 pathway activation. <b>A,</b> Schematic of CCR and sIL7, as well transgenes into cells. <b>B,</b> Transduction efficiency to express GFP only, IL7R + GFP, or secrete was measured by detecting eGFP positivity expression with flow cytometry. <b>C,</b> Concentration in the supernatant sIL7-transduced control (G-o) cytokine-free culture medium. <b>D,</b> Immunophenotype...
<div>Abstract<p>Chimeric antigen receptor (CAR) T cells can effectively treat leukemias, but sustained antitumor responses be hindered by a lack of CAR T-cell persistence. Cytotoxic effector are short-lived, and establishment CAR-T with memory to ensure immune surveillance is important. Memory depend on cytokine support, IL7 activation the (IL7R) being critical. However, IL7R surface expression negatively regulated exposure IL7. We aimed support persistence equipping IL7Rα...
<p>T cells with IL7 pathway activation expand and circulate <i>in vivo</i>. <b>A,</b> Schematic of experimental design. NSG mice were injected on day 0 10<sup>7</sup> T expressing a ffLuc reporter. BLI was conducted biweekly, peripheral blood collected days 15 30. One group treated ffLuc-only–modified intraperitoneal injections daily from 1 to 21. <b>B,</b> monitoring T-cell expansion. <b>C,</b> Quantified radiance per mouse....
<p>CCR expression does not diminish CAR T-cell antitumor activity. <b>A,</b> Schematic of the xenograft model. On day 0, NSG mice were injected via tail vein with 1 × 10<sup>6</sup> CD123<sup>+</sup> MV-4-11.ffLuc cells. In treatment groups, 2 T cells administered on 7. Cohorts: unmodified (NT), CD28.ζ CAR, and + IL7Rα CCR-T <b>B,</b> Leukemia proliferation was monitored BLI, whole-animal radiance recorded...
<p>Single-chain proximal IL7Rα CAR-T cells have decreased <i>in vivo</i> antileukemia activity. <b>A,</b> Schematic of the xenograft model. On day 0, NSG mice were injected via tail vein with 1 × 10<sup>6</sup> CD123<sup>+</sup> MV-4-11.ffLuc cells. In treatment groups, 2 CAR<sup>+</sup> T administered on 7. Cohorts: unmodified (NT, <i>n</i> = 2), CD28.ζ + sIL7 (<i>n</i> 6), CD28.IL7R.ζ and IL7R.CD28.ζ...
<p>CD123-targeted CAR and CCR can be coexpressed with maintained functionality. <b>A,</b> Schematic showing structures. <b>B,</b> Transduction efficiency measured using flow cytometric staining of Halo SNAP tags. <i>n</i> = 3 to 6 unique T-cell donors, unless noted no significant difference between groups. <b>C,</b> Measurement phosphorylated STAT5 percentage in cytokine starved, engineered T cells without activation on the immobilized...
<p>CCR expression does not diminish CAR T-cell antitumor activity. <b>A,</b> Schematic of the xenograft model. On day 0, NSG mice were injected via tail vein with 1 × 10<sup>6</sup> CD123<sup>+</sup> MV-4-11.ffLuc cells. In treatment groups, 2 T cells administered on 7. Cohorts: unmodified (NT), CD28.ζ CAR, and + IL7Rα CCR-T <b>B,</b> Leukemia proliferation was monitored BLI, whole-animal radiance recorded...